Dallas, Texas 05/22/2014 (FINANCIALSTRENDS) – Liberum Capital restated their rating of “buy” on AstraZeneca plc (ADR) (NYSE:AZN) shares in the research note that was released to investors. Currently, they have a price target of GBX 5,800 or $97.56 on the stock. Recently, numerous other analyst firms have weighed in on the AZN stock. Prime Wealth analysts have restated their rating of “buy” on the company stock in their research note to investors. They have set a price target of GBX 5,000 or $84.10 on the stock. Separately, the analysts at Societe Generale have reiterated their rating of “hold” on the AstraZeneca stock in the research note on May 15th.
They currently have set a Pt of GBX 4,661 ($78.40) on the stock. Finally, the analysts at Credit Suisse have reiterated their “neutral” rating on the company shares in a research note on May 15th. They currently have a PT GBX 4,800 ($80.74) on the stock. Six research-analysts have assigned a “sell” rating to the AZN stock, 18 have assigned a rating of “hold” and 8 have assigned a “buy” rating. Currently, the average rating on the stock is a “hold” and the average PT is GBX 4,095.91 ($68.90).
What AZN does
AstraZeneca PLC (AstraZeneca) is an international bio-pharmaceutical company that is directly involved in the discovery, development & the commercialization of various prescription medicines for 6 different areas of health care: 1- Cardiovascular, 2- Gastrointestinal, 3- Infection, 4- Neuroscience, 5- Oncology, and 6- Respiratory and Inflammation. The company has a vast range of medicines which includes different treatments for illnesses, like the antibiotic- Merrem/Meronem & the Losec/Prilosec that is used to treat acid-related diseases. The company’s products include Crestor, and Atacand, as well as Seloken/Toprol-XL, Plendil, & Onglyza. It also has products like Zestril, Symbicort & Zoladex. It owns and operates a variety of research and development, production & marketing facilities across the globe.